Everyone talks about boosting NAD+, but a new preclinical study spotlights the enzyme that may be draining it: CD38. A brain-penetrant inhibitor called CVN14 raised brain NAD+ in rats and mice, and it did nothing in mice lacking CD38. In Parkinson's models, it was linked to better dopaminergic neuron survival in culture and improved motor function in rats. But this is an experimental drug from Cerevance, tested in animals and cells, and all authors work for the company. Here is what it does and does not mean for NMN and NR buyers.
This page is available in